Overview

Cerebral Folate Deficiency (CFD) is defined as a developmental disorder in which low levels of folate are present in the brain despite the blood folate levels being within the normal range. The transport of folate into the Cerebrospinal Fluid (CSF) can often be impaired either due to genetic mutations or autoantibodies that block folate receptors. Folate is also known as vitamin B9, an essential water soluble vitamin for healthy bodily regulation such as formation of red blood cells and support of cell functionality.¹ As stated by the NHS, it is noteworthy that the intake of vitamin B9 (folate) is the most essential during pregnancy.² A reduction in its intake can lead to various issues ranging from fatigue to severe neural tube defects in a developing fetus. 

Whilst it is the most crucial to monitor folate levels during pregnancy to avoid any complications, it’s also important to consider how the low levels within the cerebrospinal fluid can impact any individual. These levels can be visualised through clinical and laboratory indicators, which would aid in the treatment provided to rectify any cerebral folate deficiency present.

Causes of cerebral folate deficiency

Cerebral folate deficiency can arise from a variety of causes, which differ between adults and fetuses. The following factors can lead to a deficiency as listed below:

• Genetic mutations (specifically the FOLR1 gene)
• Inheritance of an autosomal recessive pattern 
• Serum folate receptor-alpha (FR𝛼) autoantibodies impairing the folate transport into the brain³

Indicators of cerebral folate deficiency

The hallmark signs of cerebral folate deficiency can be differentiated into two distinct categories: Clinical indicators and Laboratory indicators.

The onset of physical symptoms can be categorised under the clinical indicators. For example, the symptoms can begin to present themselves from an early age; they range from cognitive delays such as speech complications to neurological issues like epilepsy and loss of voluntary movement (dyskinesia).⁴

Whereas laboratory indicators of cerebral folate deficiency include low concentrations of 5-methyltetrahydrofolate (5-MTHF) in the cerebrospinal fluid, in comparison to the normal overall serum folate levels.⁵ Additionally, if other tests seem inconclusive, the elevated cerebrospinal fluid protein or inflammatory markers can also be considered as characteristics indicating the deficiency. These results highlight the importance of CSF analysis in confirming the diagnosis, as routine blood tests alone may not reveal the deficiency.

Furthermore, there are other ways to confirm the diagnosis of cerebral folate deficiency. Diagnostic approaches may include imaging techniques: Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy. These scans can aid in visualising the structural or metabolic abnormalities to support the diagnosis and help exclude alternative etiologies (causes of abnormal disorders).⁶ Electroencephalography is also a valuable tool used specifically for patients presenting with seizures.⁷ These complementary investigations alongside the laboratory indicators lay out a more comprehensive assessment, especially in complex or atypical presentations.

Monitoring goals

All of these indicators are taken into consideration whilst diagnosing an individual. Thus, a treatment regime is started in which the different indicators are targeted to reverse the folate deficiency within the brain. The tracking of these indicators allows for any side effects of a drug to be detected early and for the treatment to be adjusted accordingly for a patient. All these steps are significant in giving way to developmental milestones in children and allowing an individual to have a good quality of life.

The patients and their caregivers can also actively participate in their treatment by keeping a symptom diary. By taking part in the tolerance reports given by the medical team, the treatment administered can be monitored to a significant extent, allowing for a good rate of recovery. All of these collaborative efforts can help in identifying the symptoms and whether they are cerebral folate deficiency specific. Moreover, by monitoring from both a clinical and laboratory standpoint, the communication with doctors is better facilitated, as they are better informed, paving way for effective management strategies.⁸

Challenges

Despite the promising outcomes modern science has portrayed, it is important to consider the potential challenges. In the process of investigating the levels of 5-MTHF present in the cerebrospinal fluid, a lumbar puncture must be performed. Whilst a puncture is associated with a lower incidence of discomfort, it is still an invasive procedure.⁹ This creates feasibility issues when working with young children as they may require anesthesia to relax them. This further adds the element of a procedural risk, especially when working with patients that are already exhibiting severe symptoms like loss of voluntary movement.⁴

Furthermore, whilst monitoring the indicators, it is critical to evaluate if the symptoms of CFD or the side effects of the treatment overlap with any other conditions, such as environmental factors, concurrent therapies or unrelated health illnesses. Indeed, many other illnesses are known to mimic cerebral folate deficiency, for example: Folinic acid-responses seizures (FARS) and Kearns-Sayre syndrome. FARS is a condition in which seizures and irritability mirroring that of CFD are present.⁴ Whilst in Kearns-Sayre syndrome, there is also a reduction of folate transport present.¹⁰

Also, there can be a delayed recovery from the symptoms despite early correction of CSF folate levels, which can result in mental strain. If the treatment is started late, central nervous system damage may have already occurred and potentially be irreversible.¹¹

All of these challenges are important to consider to ensure the best and earliest patient specific treatment plan as it is a treatable disease if targeted promptly.¹²

Decision making

Through confirming both clinical and biochemical factors, alongside patient daily reports, the diagnosis of Cerebral Folate Deficiency can be made.

Overall, there should be no significant adverse effects from the treatment provided, henceforth resulting in stable CSF 5-MTHF levels. However, treatment intolerance or symptoms persisting despite treatment should always be highlighted and followed up with. Thus, the patient adhering consistently by taking their medication and reporting any changes to their doctor also helps sustain improvement in their functionality. This can be managed further by scheduling long term monitoring appointments. According to the National Library of Medicine (NIH) these include regular intervals of annual assessments to help evaluate the folate levels within the cerebrospinal fluid and whether the neurologic concerns alongside developmental delays have been addressed.¹³ 

Summary

By monitoring the clinical and laboratory indicators of Cerebral Folate Deficiency, alongside a collaborative effort that integrates caregiver observations, an effective treatment response is possible. The main symptoms often experienced vary but they include cognitive delays, irritability, difficulty concentrating, and delays in reaching developmental milestones like crawling or walking. Long-term untreated folate deficiency in the cerebrospinal fluid can lead to neurological disorders like epilepsy or even nerve damage.¹⁴

To have objective measures in place, the 5-MTHF levels present in the cerebrospinal fluid remain the gold standard for assessing the exact biochemical correction required: folate supplements i.e. folinic acid.¹⁵

It should always be noted that regular and consistent evaluations allow for adjustments in treatment therapy to take place, which in turn advances the long term stability for the patient. If you are a caregiver to a young child showcasing these ongoing symptoms, consult a healthcare professional for further support. Early recognition means effective recovery.